To further explore whether PRMT3 inhibition has potential for treating tau hyperphosphorylation and the resulting neuronal dysfunction, we used PRMT3 specific inhibitor SGC707 to treat in vitro tauopathy cell models induced by okadaic acid (OA). The gene discussed is MAPT; the disease is tauopathy.